Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

Leyvraz, Serge; Piperno‐Neumann, Sophie; Suciu, Stefan; Baurain, Jean‐François; Zdzienicki, Marcin; Testori, Alessandro; Marshall, Ernest; Scheulen, M. E.; Jouary, Thomas; Négrier, Sylvie; Vermorken, Jan B.; Kaempgen, Eckhart; Durando, Xavier; Schadendorf, Dirk; Gurunath, Ravichandra Karra; Keilholz, Ulrich

doi:10.1093/annonc/mdt585

Cited by 111 publications

(88 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Median os was 10 months in patients who received complete surgery plus chemotherapy 97 . Similar findings have been reported elsewhere 98 . Further study incorporating new agents, especially immunotherapeutic agents, will be of interest, and clinical trial participation is encouraged.…”

Section: Surgical Resection In the Setting Of Metastatic Diseasesupporting

confidence: 93%

Management of Uveal Melanoma: A Consensus-Based Provincial Clinical Practice Guideline

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Surgical Resection In the Setting Of Metastatic Diseasesupporting

confidence: 93%

Management of Uveal Melanoma: A Consensus-Based Provincial Clinical Practice Guideline

et al. 2016

View full text Add to dashboard Cite

show abstract

“…3 Because uveal melanoma is rare, few randomized clinical trials are performed. [15][16][17] Thus, there is a need for validated staging systems to adjust for differences in case mix in non-randomized phase II studies that would aid in selecting patients for trials, in stratifying the analysis, and in interpreting the results. 10,18 Recently, a nomogram-based system for this purpose was developed and externally validated.…”

Section: A N U S C R I P Tmentioning

confidence: 99%

Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group

Kivelä

Piperno‐Neumann

Desjardins

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The European Organization for Research and Treatment of Cancer (EORTC) 18021 study, a randomized phase 3 trial, HIA was compared to intravenous delivery of fotemustine in patients with previously untreated, unresectable liver-only metastases from ocular melanoma [109]. Although the study found an improved overall response rate with HIA compared with intravenous fotemustine (11% vs. 2%, respectively), the study failed to demonstrate a difference between the two groups with respect to overall survival.…”

Section: Locoregional Treatments Of Liver Metastasismentioning

confidence: 99%

Uveal Melanoma: A Review of the Literature

2018

View full text Add to dashboard Cite

Melanomas affecting different components of the uvea occur with differing frequencies and clinical presentations. Uveal melanoma is diagnosed via funduscopic exam and ancillary tests. These lesions may present with visual findings or incidental findings on physical exam. Metastasis occurs in approximately half of all patients with primary uveal melanoma. The liver is the most common site of metastasis. Enucleation was at one time considered the definitive local treatment for primary uveal melanoma, but has been largely replaced by other therapeutic procedures that aim to prevent metastasis while preserving vision. Unfortunately, metastasis of uveal melanoma almost always proves to be fatal. The current treatment of metastatic uveal melanoma is limited by the intrinsic resistance of uveal melanoma to conventional systemic therapies. Advancements in molecular biology have resulted in the identification of a number of promising prognostic and therapeutic targets. Early detection and therapy are important factors in disease survival. It is imperative that the treating physician be familiar with the clinical features of uveal melanoma and distinguish it from mimickers in order to ensure effective and timely treatment.

show abstract

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

Cited by 111 publications

References 25 publications

Management of Uveal Melanoma: A Consensus-Based Provincial Clinical Practice Guideline

Management of Uveal Melanoma: A Consensus-Based Provincial Clinical Practice Guideline

Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group

Uveal Melanoma: A Review of the Literature

Contact Info

Product

Resources

About